What's new

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised

Feb 20, 2025 - 15:02
 0
Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Imfinzi, durvalumab, Date of authorisation: 21/09/2018, Revision: 24, Status: Authorised
Read More

Tags:

Previous Article

Orphan designation: volixibat potassium Treatment of primary biliary cholangitis...

Next Article

Orphan designation: Allogenic umbilical cord-derived osteoblast cells Treatment ...

Related Posts

Human medicines European public assessment report (EPAR): Aprovel, irbesartan, Date of authorisation: 26/08/1997, Revision: 50, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 11, 2025  0

EMEA-003490-PIP01-23

EMEA-003490-PIP01-23

Feb 13, 2025  0

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) – June 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 June 2025, 10:00 (CEST) to 26 June 2025, 12:00 (CEST)

Meeting of the Executive Steering Group on Shortages an...

Feb 9, 2025  0